Home Cart 0 Sign in  
X

[ CAS No. 17347-32-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 17347-32-9
Chemical Structure| 17347-32-9
Chemical Structure| 17347-32-9
Structure of 17347-32-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 17347-32-9 ]

Related Doc. of [ 17347-32-9 ]

Alternatived Products of [ 17347-32-9 ]

Product Details of [ 17347-32-9 ]

CAS No. :17347-32-9 MDL No. :MFCD11226847
Formula : C8H5BrS Boiling Point : -
Linear Structure Formula :- InChI Key :OQIMJOXSDVGEBU-UHFFFAOYSA-N
M.W : 213.09 Pubchem ID :12744400
Synonyms :

Calculated chemistry of [ 17347-32-9 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 0.0
Num. H-bond donors : 0.0
Molar Refractivity : 49.53
TPSA : 28.24 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.02 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.41
Log Po/w (XLOGP3) : 3.63
Log Po/w (WLOGP) : 3.66
Log Po/w (MLOGP) : 3.38
Log Po/w (SILICOS-IT) : 4.37
Consensus Log Po/w : 3.49

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.11
Solubility : 0.0164 mg/ml ; 0.0000769 mol/l
Class : Moderately soluble
Log S (Ali) : -3.91
Solubility : 0.0262 mg/ml ; 0.000123 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.2
Solubility : 0.0134 mg/ml ; 0.000063 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 2.06

Safety of [ 17347-32-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P305+P351+P338 UN#:N/A
Hazard Statements:H302-H319-H413 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 17347-32-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 17347-32-9 ]
  • Downstream synthetic route of [ 17347-32-9 ]

[ 17347-32-9 ] Synthesis Path-Upstream   1~24

  • 1
  • [ 19075-58-2 ]
  • [ 17347-32-9 ]
YieldReaction ConditionsOperation in experiment
83% With 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl acetamide at 200℃; for 1.16667 h; Microwave irradiation [00854] Part C. Preparation of 6-bromobenzo[Z>]thiophene.; [00855] The product from Part B (0.7Og, 2.73mmol) and DBU (1.35mL, 8.94mmol) were combined inDMA (6mL) in a sealed tube and heated at 2000C in a microwave reactor for 70min. The resulting dark solution was diluted with 1 M HCl (2OmL) and extracted with CH2Cl2 (2 x 2OmL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo, and the crude product was purified by column chromatography on silica gel using CH2Cl2 as the eluent to give the title compound as an oil (0.484g 83percent).
78%
Stage #1: With 1,8-diazabicyclo[5.4.0]undec-7-ene In ISOPROPYLAMIDE at 20 - 200℃; for 1 h; Microwave irradiation
Stage #2: With hydrogenchloride In ISOPROPYLAMIDE; water
DBU (1.21g, 8.00mmol) was added to a stirred solution of 6-bromo- benzo[b]thiophene-2-carboxylic acid (I-25b: 2.4g, 8.85mmol) in DMA (4mL) at room temperature and the resulting mixture was heated in microwave at 200°C for 1 hour. The reaction was monitored by TLC (50percent ethyl acetate in hexane). The reaction mixture was acidified with IN HCl and extracted with ethyl acetate. The organic layer was concentrated and purified by column chromatography on silica gel (100percent hexane) to afford 320mg of the product (78percent yield).1H NMR (CDC13, 300 MHZ): δ 8.18-8.0 (d, 1H), 7.7-7.6 (d, 1H), 7.5-7.59 (d, 1H), 7.59-7.42 (d, 1H), 7.3-7.29 (d, 1H).
78% With acetic acid; silver carbonate In dimethyl sulfoxide at 120℃; for 16 h; A mixture 3a or 4b (0.5 mmol), Ag2CO3 (0.05 mmol), AcOH(0.025 mmol) in DMSO (1.0 mL)was stirred at 120 °C. After 16 h, thereactionwas cooled down to room temperature and quenched with1 M hydrochloric acid solution (2 mL) and the aqueous phaseextracted with ethyl acetate. The combined organic layers werewashed with brine and dried sodium sulfate, filtered, and the solventswere removed under reduced pressure to give analyticallypure 4a or 4b.
73% at 185℃; for 2 h; Compound   23 (3.67 g, 14.3 mmol) and   copper powder (0.45 g, 7.1 mmol) were suspended in   quinoline (18 mL) and heated at 185 °C for 2 h. After cooling down to rt,   EtOAc (25 mL) was added and the suspension filtered. The solid was washed with further EtOAc and the combined organic solutions washed with 2 N HCl (2 × 50 mL). After drying (MgSO4), filtration and evaporation in vacuo, the residue was purified by chromatography on silica with pentane to afford the desired   material (2.21 g) as a crystalline white solid. Yield: 73percent. 1H NMR (CDCl3), δ: 7.31 (dd, J = 5.4, 0.9, 1H, ArH), 7.43 (d, J = 5.4, 1H, ArH), 7.48 (dd, J = 8.4, 1.6, 1H, ArH), 7.69 (d, J = 8.6, 1H, ArH), 8.03 (d, J = 1.8, 1H, ArH).
62%
Stage #1: at 20 - 195℃; for 10 h;
Stage #2: at 0 - 20℃; for 1 h;
Preparation 46 <n="38"/>6-Bromo-benzorbithiopheneCopper powder (100 g, 1.57 mol) is added to a solution of 6-bromo-benzo[b]-tbdopherie-2- earboxylie acid (1.04 Kg, 4.04 mol) in quinoline (2.5 L) at room temperature. The reaction mixture is heated to reflux (195 °C) for 1O h. The reaction mixture is cooled to room temperature and poured onto ice (2.5 Kg). Concentrated HCl (2.5 L) is added while stirring the resulting mass for Ih. The reaction mixture is extracted with hexane (4 x 3 L) and washed with dilute HCl (1 x 2 L), aqueous bicarbonate (1 x 5 L), and brine solution (1 x 5 L). The layers are separated and the organic layer is dried over sodium sulfate and concentrated to give the title compound (0.54 Kg, 62percent ) as a light yellow solid.

Reference: [1] Journal of Medicinal Chemistry, 2016, vol. 59, # 1, p. 264 - 281
[2] Tetrahedron Letters, 2004, vol. 45, # 52, p. 9645 - 9647
[3] Patent: WO2009/39134, 2009, A1, . Location in patent: Page/Page column 159
[4] Patent: WO2012/149413, 2012, A1, . Location in patent: Page/Page column 59
[5] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 538 - 550
[6] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 5, p. 1284 - 1304
[7] Patent: WO2007/92751, 2007, A2, . Location in patent: Page/Page column 36-37
  • 2
  • [ 737802-11-8 ]
  • [ 17347-32-9 ]
YieldReaction ConditionsOperation in experiment
95% With boron trifluoride diethyl etherate In acetic acid at 20 - 120℃; for 0.0833333 h; To a room temperature solution OF 6-BROMO-2, 3-dihydro-benzo [b] thiophen-3-ol (785 mg, 3.39 mmol) in HOAC (7 mL) is added boron trifluoride diethyl etherate (1. 44 G, 10.2 mmol) and the reaction mixture is placed into a 120 C oil bath. After 5 min, the reaction is cooled to room temperature and basified to-pH 11 using 2 M NaOH. The aqueous suspension is extracted with ET2O (2 X 200 mL) and the combined organic layer is dried (MGS04), filtered and concentrated to afford the sub-title compound (689 mg, 95percent) as an off-white solid. RF 0. 70 (4: 1 HEX/ETOAC). mp 48-50 C. 'H NMR (300 MHz, CDCl3) 8 7.29 (d, J= 5.4 Hz, 1H), 7.41 (d, J= 5. 4 Hz, 1H), 7.46 (dd, J= = 1. 8,8. 5 Hz, 1H), 7.66 (d, J= 8.5 Hz, 1H), 8.01 (M, 1H).
Reference: [1] Patent: WO2004/67529, 2004, A1, . Location in patent: Page 162
  • 3
  • [ 17347-29-4 ]
  • [ 17347-32-9 ]
YieldReaction ConditionsOperation in experiment
72% With polyphosphoric acid In 1,2-dichloro-ethane for 3 h; Reflux A solution of compound B-197 (50 g, 0.16 mol) in 1 ,2-dichloroethane (500 mL) was added dropwise to a mixture of polyphosphoric acid (100 g) in 1 ,2-dichloroethane (500 mL) at reflux. The mixture was stirred at reflux for 3 hours. On completion, the reaction mixture was cooled to room temperature and quenched with water (200 mL). The resulting mixture was extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, concentrated in vacuo and purified by silica gel chromatography [petroleum ether: ethyl acetate = 20: 1 ] to give compound B-198 (25 g, 72percent yield) as a colorless oil. LCMS: (ES+) m/z (M+H)+ = 215.1 , tR= 0.945.
27% With PPA In chlorobenzene for 3.5 h; Heating / reflux Into a mixture of polyphosphoric acid (160 g) in chlorobenzene (1 L) at reflux is added a solution of the crude 3-bromobenzenethioacetaldehyde diethyl acetal (60.06 g, 196.76 mmol) in chlorobenzene (500 mL) via an addition funnel over a 1.5 h period. Upon complete addition, the mixture is heated at reflux for an additional 2 h and is then allowed to cool to room temperature. The chlorobenzene layer is decanted from the mixture and washed with saturated aqueous NaCl (500 mL). The aqueous layer is used to dilute the PPA, which is then extracted with Et2O (3 x 500 mL). The combined organic layers are dried over MgSO4, filtered and concentrated under reduced pressure. The residue is then purified by silica gel chromatography (100percent hexanes). The purified fractions are combined and concentrated under reduced pressure to give 6- bromobenzo[b]thiophene as a white crystal (11.59 g, 27percent). mp 54.8-58.3 °C. IR (KBr) 3017, 1586, 1448, 1067, 814 cm4. Ion Spray MS 211.9, 213.9 (M)+.
25% With PPA; Polyphosphoric acid (PPA) In benzene for 6 h; Heating / reflux Step B: Synthesis of 6-bromobenzo[δ]thiophene as an intermediate; [0183] A mixture of (3-bromophenyl)(2,2-diethoxyethyl)sulfane (3.42 g, 11.2 mmol), PPA (1.0 g), and benzene (30 mL) was refluxed for 6 h. After cooling to room temperature, the mixture was poured into water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over sodium sulfate, and filtered. Evaporation of the solvents and purification by chromatography (silica, hexanes) gave 6- bromobenzo[6]thiophene (0.607 g, 25percent) as a white solid: 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J= 8.1 Hz, IH), 7.54-7.47 (m, 3H), 7.19 (t, J= 7.8 Hz, IH).
Reference: [1] Patent: WO2015/66371, 2015, A1, . Location in patent: Paragraph 00392-00393
[2] Patent: WO2006/107784, 2006, A1, . Location in patent: Page/Page column 135
[3] Patent: WO2009/42907, 2009, A1, . Location in patent: Page/Page column 73
  • 4
  • [ 6320-01-0 ]
  • [ 2032-35-1 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: US6664274, 2003, B1, . Location in patent: Page column 23; 24
  • 5
  • [ 19296-69-6 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: US2006/52378, 2006, A1, . Location in patent: Page/Page column 129-130
[2] Patent: WO2009/26345, 2009, A1, . Location in patent: Page/Page column 42-43
[3] Patent: WO2009/49028, 2009, A1, . Location in patent: Page/Page column 88
[4] Patent: US2004/186134, 2004, A1, . Location in patent: Page 24-25
[5] Patent: WO2014/186035, 2014, A1, . Location in patent: Page/Page column 192
  • 6
  • [ 17347-29-4 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: US6828332, 2004, B1, . Location in patent: Page column 31
[2] Patent: EP3239143, 2017, A2, . Location in patent: Paragraph 0610
  • 7
  • [ 6320-01-0 ]
  • [ 17347-32-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2003, vol. 46, # 12, p. 2446 - 2455
[2] Journal of the Chemical Society, 1957, p. 2624,2628
[3] Patent: WO2015/66371, 2015, A1,
[4] Patent: WO2006/107784, 2006, A1,
  • 8
  • [ 19296-69-6 ]
  • [ 17347-32-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2003, vol. 46, # 12, p. 2446 - 2455
  • 9
  • [ 57848-46-1 ]
  • [ 17347-32-9 ]
Reference: [1] Patent: WO2012/149413, 2012, A1,
[2] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 5, p. 1284 - 1304
[3] Journal of Medicinal Chemistry, 2016, vol. 59, # 1, p. 264 - 281
[4] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 538 - 550
  • 10
  • [ 360576-01-8 ]
  • [ 17347-32-9 ]
Reference: [1] Patent: WO2012/149413, 2012, A1,
[2] Journal of Medicinal Chemistry, 2016, vol. 59, # 1, p. 264 - 281
[3] European Journal of Medicinal Chemistry, 2017, vol. 125, p. 538 - 550
  • 11
  • [ 6320-01-0 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: WO2014/186035, 2014, A1,
[2] Patent: EP3239143, 2017, A2,
  • 12
  • [ 105191-64-8 ]
  • [ 17347-32-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 5, p. 1284 - 1304
  • 13
  • [ 90001-42-6 ]
  • [ 17347-32-9 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 2624,2628
  • 14
  • [ 3996-39-2 ]
  • [ 17347-32-9 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 2624,2628
  • 15
  • [ 79603-03-5 ]
  • [ 17347-32-9 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 2624,2628
  • 16
  • [ 101774-28-1 ]
  • [ 17347-32-9 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 2624,2628
  • 17
  • [ 6320-01-0 ]
  • [ 2032-35-1 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: US6664274, 2003, B1, . Location in patent: Page column 23; 24
  • 18
  • [ 19296-69-6 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: US2006/52378, 2006, A1, . Location in patent: Page/Page column 129-130
[2] Patent: WO2009/26345, 2009, A1, . Location in patent: Page/Page column 42-43
[3] Patent: WO2009/49028, 2009, A1, . Location in patent: Page/Page column 88
[4] Patent: US2004/186134, 2004, A1, . Location in patent: Page 24-25
[5] Patent: WO2014/186035, 2014, A1, . Location in patent: Page/Page column 192
  • 19
  • [ 17347-29-4 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: US6828332, 2004, B1, . Location in patent: Page column 31
[2] Patent: EP3239143, 2017, A2, . Location in patent: Paragraph 0610
  • 20
  • [ 6320-01-0 ]
  • [ 17347-32-9 ]
  • [ 5118-13-8 ]
Reference: [1] Patent: WO2014/186035, 2014, A1,
[2] Patent: EP3239143, 2017, A2,
  • 21
  • [ 17347-32-9 ]
  • [ 68-12-2 ]
  • [ 6386-80-7 ]
YieldReaction ConditionsOperation in experiment
72%
Stage #1: With magnesium In tetrahydrofuran for 2 h; Reflux
Stage #2: at 0 - 20℃;
In a 25 mL three-necked flask, magnesium (257 mg, 10.6 mmol) was suspended in THF,(1.7 mL) and heated to reflux. A solution of 6-bromobenzo[b]thiophene (1.5 g, 7.04 mmol) in THF (8.3 mL) was added dropwise. The reaction mixture was stuffed at reflux for 2 h, thencooled to 0°C. N,N-Dimethylformamide (1.03 g, 1.09 ml, 14.1 mmol) was added dropwise and the reaction allowed to warm up to room temperature. The resulting green suspension was stirred overnight then concentrated. The residue was purified by chromatography over silica gel. One fraction was isolated and dried in vacuo, affording 821 mg (72percent) of benzo[b]thiophene-6- carbaldehyde as a yellow oil.
Reference: [1] Patent: WO2014/86663, 2014, A1, . Location in patent: Page/Page column 61
  • 22
  • [ 2591-86-8 ]
  • [ 17347-32-9 ]
  • [ 106-93-4 ]
  • [ 6386-80-7 ]
Reference: [1] Patent: US4664693, 1987, A,
[2] Patent: EP125059, 1991, B1,
  • 23
  • [ 17347-32-9 ]
  • [ 6386-80-7 ]
Reference: [1] Patent: WO2015/66371, 2015, A1,
  • 24
  • [ 17347-32-9 ]
  • [ 6179-28-8 ]
Reference: [1] Patent: WO2015/66371, 2015, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 17347-32-9 ]

Bromides

Chemical Structure| 4923-87-9

[ 4923-87-9 ]

5-Bromobenzothiophene

Similarity: 0.96

Chemical Structure| 1423-61-6

[ 1423-61-6 ]

7-Bromobenzo[b]thiophene

Similarity: 0.91

Chemical Structure| 40133-22-0

[ 40133-22-0 ]

2-(4-Bromophenyl)thiophene

Similarity: 0.85

Chemical Structure| 5118-13-8

[ 5118-13-8 ]

4-Bromobenzo[b]thiophene

Similarity: 0.84

Chemical Structure| 118621-30-0

[ 118621-30-0 ]

2-(4-Bromophenyl)-5-phenylthiophene

Similarity: 0.84

Related Parent Nucleus of
[ 17347-32-9 ]

Benzothiophenes

Chemical Structure| 4923-87-9

[ 4923-87-9 ]

5-Bromobenzothiophene

Similarity: 0.96

Chemical Structure| 1423-61-6

[ 1423-61-6 ]

7-Bromobenzo[b]thiophene

Similarity: 0.91

Chemical Structure| 5118-13-8

[ 5118-13-8 ]

4-Bromobenzo[b]thiophene

Similarity: 0.84

Chemical Structure| 95-15-8

[ 95-15-8 ]

Thianaphthene

Similarity: 0.76

Chemical Structure| 1195-14-8

[ 1195-14-8 ]

2-Methylbenzo[b]thiophene

Similarity: 0.74